These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26169891)

  • 1. Tolerance of Fondaparinux in Immediate-type Hypersensitivity to Heparins.
    Trog LM; Kahle B; Schindewolf M; Jappe U; Ludwig RJ
    Am J Med; 2015 Nov; 128(11):e21-2. PubMed ID: 26169891
    [No Abstract]   [Full Text] [Related]  

  • 2. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux.
    Harr T; Scherer K; Tsakiris DA; Bircher AJ
    Allergy; 2006 Jun; 61(6):787-8. PubMed ID: 16677252
    [No Abstract]   [Full Text] [Related]  

  • 3. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids.
    Gerhardt A; Zotz RB; Stockschlaeder M; Scharf RE
    Thromb Haemost; 2007 Mar; 97(3):496-7. PubMed ID: 17334521
    [No Abstract]   [Full Text] [Related]  

  • 4. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy.
    Maetzke J; Hinrichs R; Staib G; Scharffetter-Kochanek K
    Allergy; 2004 Feb; 59(2):237-8. PubMed ID: 14763948
    [No Abstract]   [Full Text] [Related]  

  • 5. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy.
    Wijesiriwardana A; Lees DA; Lush C
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):147-9. PubMed ID: 16479197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
    Parody R; Oliver A; Souto JC; Fontcuberta J
    Haematologica; 2003 Nov; 88(11):ECR32. PubMed ID: 14607764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux (Arixtra), a new anticoagulant.
    Med Lett Drugs Ther; 2002 May; 44(1130):43-4. PubMed ID: 12011755
    [No Abstract]   [Full Text] [Related]  

  • 8. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.
    Alsaleh KA; Al-Nasser SM; Bates SM; Patel A; Warkentin TE; Arnold DM
    Am J Hematol; 2008 Nov; 83(11):876-8. PubMed ID: 18803278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia.
    D'Angelo A; Valle PD; Fattorini A; Luciano C
    Thromb Haemost; 2006 Mar; 95(3):573-5. PubMed ID: 16525590
    [No Abstract]   [Full Text] [Related]  

  • 10. [Fondaparinux for thrombosis prevention after orthopaedic surgery: a revolution?].
    Monreal M
    Med Clin (Barc); 2003 May; 120(20):775-6. PubMed ID: 12797930
    [No Abstract]   [Full Text] [Related]  

  • 11. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evidence for thrombosis prophylaxis to high-risk patients].
    Själander A; Jansson JH; Bergqvist D; Eriksson H; Svensson P
    Lakartidningen; 2007 May 14-29; 104(20-21):1585-7. PubMed ID: 17564265
    [No Abstract]   [Full Text] [Related]  

  • 13. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of venous thromboembolism with fondaparinux.
    Priestley M
    N Engl J Med; 2002 Mar; 346(12):940-2; author reply 940-2. PubMed ID: 11911134
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances and contemporary issues in prophylaxis for deep vein thrombosis.
    Hirsh J
    Chest; 2003 Dec; 124(6 Suppl):347S-348S. PubMed ID: 14668416
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-molecular-weight heparins and heparinoids.
    Williamson OD; Street AM
    Med J Aust; 2003 Apr; 178(8):414; author reply 414-5. PubMed ID: 12776722
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on low molecular weight heparins at the beginning of third millennium. Focus on reviparin.
    Del Bono R; Martini G; Volpi R
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):950-9. PubMed ID: 21845806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin-induced thrombocytopenia successfully treated with fondaparinux.
    Seldrum S; Lambert M; Hainaut P
    Acta Clin Belg; 2009; 64(2):144-6. PubMed ID: 19432027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed hypersensitivity to heparin in a patient with cancer: fondaparinux may be safe but needs to be tested.
    Colagiovanni A; Rizzi A; Buonomo A; De Pasquale T; Pecora V; Sabato V; Aruanno A; Pascolini L; Nucera E; Schiavino D
    Contact Dermatitis; 2010 Aug; 63(2):107-8. PubMed ID: 20629676
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fondaparinux and lepirudin as therapeutic alternatives in a disseminated eczematous skin reaction to low-molecular-weight heparin].
    Santiago Sánchez-Mateos DI; Eguren C; de Argila D; Sánchez-Pérez J
    Actas Dermosifiliogr; 2010 Jul; 101(6):556-8. PubMed ID: 20738979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.